

2019 Future of Coronary Artery Disease (CAD)/Ischemic Heart Disease R&D Pipeline Drugs and Companies- Analysis of Global Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/289188BC885EN.html>

Date: January 2019

Pages: 120

Price: US\$ 2,199.00 (Single User License)

ID: 289188BC885EN

Abstracts

The global demand for Coronary Artery Disease (CAD) (Ischemic Heart Disease) treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline companies from advancing their products into Phase 3 or Phase 4.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Report Description

The H1 2019 pipeline review report on Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline compounds.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline guide presents information on all active drugs currently being developed for Coronary Artery Disease (CAD) (Ischemic Heart Disease). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Coronary Artery Disease (CAD) (Ischemic Heart Disease) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Coronary Artery Disease (CAD) (Ischemic Heart Disease) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline report includes

An overview of Coronary Artery Disease (CAD) (Ischemic Heart Disease) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials

etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Candidates

4. ADVANCECOR GMBH CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 4.1 advanceCor GmbH Business Profile
- 4.2 advanceCor GmbH Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity

- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. ANGIOSOMA INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 5.1 AngioSoma Inc Business Profile
- 5.2 AngioSoma Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. APT THERAPEUTICS INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 6.1 APT Therapeutics Inc Business Profile
- 6.2 APT Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status

- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. ASCENDIA PHARMACEUTICALS LLC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 7.1 Ascendia Pharmaceuticals LLC Business Profile
- 7.2 Ascendia Pharmaceuticals LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 7.2.1 Drug Snapshot
 - 7.2.1.1 Originator
 - 7.2.1.2 Collaborator/Co-Developer
 - 7.2.1.3 Route of Administration
 - 7.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 7.2.1.5 Area
 - 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. ASDERA CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 8.1 Asdera Business Profile
- 8.2 Asdera Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action

8.6 Clinical/Pre-clinical Trial Details

8.7 Latest Drug Developments

9. ASTRAZENECA PLC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

9.1 AstraZeneca Plc Business Profile

9.2 AstraZeneca Plc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

9.2.1 Drug Snapshot

9.2.1.1 Originator

9.2.1.2 Collaborator/Co-Developer

9.2.1.3 Route of Administration

9.2.1.4 Orphan Drug/Fast Track/Special Designation

9.2.1.5 Area

9.2.1.6 Type of Molecular Entity

9.3 Current Status

9.4 Drug Overview

9.5 Drug Mechanism of Action

9.6 Clinical/Pre-clinical Trial Details

9.7 Latest Drug Developments

10. BAYER HEALTHCARE PHARMACEUTICALS CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

10.1 Bayer HealthCare Pharmaceuticals Business Profile

10.2 Bayer HealthCare Pharmaceuticals Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

10.2.1 Drug Snapshot

10.2.1.1 Originator

10.2.1.2 Collaborator/Co-Developer

10.2.1.3 Route of Administration

10.2.1.4 Orphan Drug/Fast Track/Special Designation

10.2.1.5 Area

10.2.1.6 Type of Molecular Entity

10.3 Current Status

10.4 Drug Overview

10.5 Drug Mechanism of Action

10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

11. BIO-THERA SOLUTIONS LTD CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

11.1 Bio-Thera Solutions Ltd Business Profile

11.2 Bio-Thera Solutions Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

11.2.1 Drug Snapshot

11.2.1.1 Originator

11.2.1.2 Collaborator/Co-Developer

11.2.1.3 Route of Administration

11.2.1.4 Orphan Drug/Fast Track/Special Designation

11.2.1.5 Area

11.2.1.6 Type of Molecular Entity

11.3 Current Status

11.4 Drug Overview

11.5 Drug Mechanism of Action

11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

12. BISCAYNE PHARMACEUTICALS INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

12.1 Biscayne Pharmaceuticals Inc Business Profile

12.2 Biscayne Pharmaceuticals Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

13. BRACCO IMAGING S.P.A. CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

13.1 Bracco Imaging S.p.A. Business Profile

13.2 Bracco Imaging S.p.A. Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Drug Details

13.2.1 Drug Snapshot

13.2.1.1 Originator

13.2.1.2 Collaborator/Co-Developer

13.2.1.3 Route of Administration

13.2.1.4 Orphan Drug/Fast Track/Special Designation

13.2.1.5 Area

13.2.1.6 Type of Molecular Entity

13.3 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14. CAPRICOR THERAPEUTICS INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

14.1 Capricor Therapeutics Inc Business Profile

14.2 Capricor Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

14.2.1 Drug Snapshot

14.2.1.1 Originator

14.2.1.2 Collaborator/Co-Developer

14.2.1.3 Route of Administration

14.2.1.4 Orphan Drug/Fast Track/Special Designation

14.2.1.5 Area

14.2.1.6 Type of Molecular Entity

14.3 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15. CARDIOVASCULAR BIOTHERAPEUTICS INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

15.1 CardioVascular BioTherapeutics Inc Business Profile

15.2 CardioVascular BioTherapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

15.2.1 Drug Snapshot

15.2.1.1 Originator

15.2.1.2 Collaborator/Co-Developer

15.2.1.3 Route of Administration

15.2.1.4 Orphan Drug/Fast Track/Special Designation

15.2.1.5 Area

15.2.1.6 Type of Molecular Entity

15.3 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16. CSL LTD CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

16.1 CSL Ltd Business Profile

16.2 CSL Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

16.2.1 Drug Snapshot

16.2.1.1 Originator

16.2.1.2 Collaborator/Co-Developer

16.2.1.3 Route of Administration

16.2.1.4 Orphan Drug/Fast Track/Special Designation

16.2.1.5 Area

16.2.1.6 Type of Molecular Entity

16.3 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

17. DALCOR PHARMACEUTICALS INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 17.1 DalCor Pharmaceuticals Inc Business Profile
- 17.2 DalCor Pharmaceuticals Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. DIAPIN THERAPEUTICS LLC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 18.1 Diapin Therapeutics LLC Business Profile
- 18.2 Diapin Therapeutics LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 18.2.1 Drug Snapshot
 - 18.2.1.1 Originator
 - 18.2.1.2 Collaborator/Co-Developer
 - 18.2.1.3 Route of Administration
 - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 18.2.1.5 Area
 - 18.2.1.6 Type of Molecular Entity
- 18.3 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19. GILEAD SCIENCES INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

19.1 Gilead Sciences Inc Business Profile

19.2 Gilead Sciences Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Drug Details

19.2.1 Drug Snapshot

19.2.1.1 Originator

19.2.1.2 Collaborator/Co-Developer

19.2.1.3 Route of Administration

19.2.1.4 Orphan Drug/Fast Track/Special Designation

19.2.1.5 Area

19.2.1.6 Type of Molecular Entity

19.3 Current Status

19.4 Drug Overview

19.5 Drug Mechanism of Action

19.6 Clinical/Pre-clinical Trial Details

19.7 Latest Drug Developments

20. HEMOSTEMIX INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

20.1 Hemostemix Inc Business Profile

20.2 Hemostemix Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

20.2.1 Drug Snapshot

20.2.1.1 Originator

20.2.1.2 Collaborator/Co-Developer

20.2.1.3 Route of Administration

20.2.1.4 Orphan Drug/Fast Track/Special Designation

20.2.1.5 Area

20.2.1.6 Type of Molecular Entity

20.3 Current Status

20.4 Drug Overview

20.5 Drug Mechanism of Action

20.6 Clinical/Pre-clinical Trial Details

20.7 Latest Drug Developments

21. IDORSIA LTD CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

21.1 Idorsia Ltd Business Profile

21.2 Idorsia Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

21.2.1 Drug Snapshot

21.2.1.1 Originator

21.2.1.2 Collaborator/Co-Developer

21.2.1.3 Route of Administration

21.2.1.4 Orphan Drug/Fast Track/Special Designation

21.2.1.5 Area

21.2.1.6 Type of Molecular Entity

21.3 Current Status

21.4 Drug Overview

21.5 Drug Mechanism of Action

21.6 Clinical/Pre-clinical Trial Details

21.7 Latest Drug Developments

22. JAAN BIOTHERAPEUTICS LLC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

22.1 Jaan Biotherapeutics LLC Business Profile

22.2 Jaan Biotherapeutics LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

22.2.1 Drug Snapshot

22.2.1.1 Originator

22.2.1.2 Collaborator/Co-Developer

22.2.1.3 Route of Administration

22.2.1.4 Orphan Drug/Fast Track/Special Designation

22.2.1.5 Area

22.2.1.6 Type of Molecular Entity

22.3 Current Status

22.4 Drug Overview

22.5 Drug Mechanism of Action

22.6 Clinical/Pre-clinical Trial Details

22.7 Latest Drug Developments

23. LIPIMETIX DEVELOPMENT INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

23.1 LipimetiX Development Inc Business Profile

23.2 LipimetiX Development Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

23.2.1 Drug Snapshot

23.2.1.1 Originator

23.2.1.2 Collaborator/Co-Developer

23.2.1.3 Route of Administration

23.2.1.4 Orphan Drug/Fast Track/Special Designation

23.2.1.5 Area

23.2.1.6 Type of Molecular Entity

23.3 Current Status

23.4 Drug Overview

23.5 Drug Mechanism of Action

23.6 Clinical/Pre-clinical Trial Details

23.7 Latest Drug Developments

24. MEDIMMUNE LLC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

24.1 MedImmune LLC Business Profile

24.2 MedImmune LLC Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

24.2.1 Drug Snapshot

24.2.1.1 Originator

24.2.1.2 Collaborator/Co-Developer

24.2.1.3 Route of Administration

24.2.1.4 Orphan Drug/Fast Track/Special Designation

24.2.1.5 Area

24.2.1.6 Type of Molecular Entity

24.3 Current Status

24.4 Drug Overview

24.5 Drug Mechanism of Action

24.6 Clinical/Pre-clinical Trial Details

24.7 Latest Drug Developments

25. MERCK & CO INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

25.1 Merck & Co Inc Business Profile

25.2 Merck & Co Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details

25.2.1 Drug Snapshot

- 25.2.1.1 Originator
- 25.2.1.2 Collaborator/Co-Developer
- 25.2.1.3 Route of Administration
- 25.2.1.4 Orphan Drug/Fast Track/Special Designation
- 25.2.1.5 Area
- 25.2.1.6 Type of Molecular Entity
- 25.3 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26. ORION CORPORATION CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 26.1 Orion Corporation Business Profile
- 26.2 Orion Corporation Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 26.2.1 Drug Snapshot
 - 26.2.1.1 Originator
 - 26.2.1.2 Collaborator/Co-Developer
 - 26.2.1.3 Route of Administration
 - 26.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 26.2.1.5 Area
 - 26.2.1.6 Type of Molecular Entity
- 26.3 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27. PHARMAHUNGARY CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 27.1 Pharmahungary Business Profile
- 27.2 Pharmahungary Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 27.2.1 Drug Snapshot
 - 27.2.1.1 Originator

- 27.2.1.2 Collaborator/Co-Developer
- 27.2.1.3 Route of Administration
- 27.2.1.4 Orphan Drug/Fast Track/Special Designation
- 27.2.1.5 Area
- 27.2.1.6 Type of Molecular Entity
- 27.3 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28. PROTEON THERAPEUTICS INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 28.1 Proteon Therapeutics Inc Business Profile
- 28.2 Proteon Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 28.2.1 Drug Snapshot
 - 28.2.1.1 Originator
 - 28.2.1.2 Collaborator/Co-Developer
 - 28.2.1.3 Route of Administration
 - 28.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 28.2.1.5 Area
 - 28.2.1.6 Type of Molecular Entity
- 28.3 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

29. RECARDIO, INC. CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 29.1 Recardio, Inc. Business Profile
- 29.2 Recardio, Inc. Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 29.2.1 Drug Snapshot
 - 29.2.1.1 Originator
 - 29.2.1.2 Collaborator/Co-Developer

- 29.2.1.3 Route of Administration
- 29.2.1.4 Orphan Drug/Fast Track/Special Designation
- 29.2.1.5 Area
- 29.2.1.6 Type of Molecular Entity
- 29.3 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action
- 29.6 Clinical/Pre-clinical Trial Details
- 29.7 Latest Drug Developments

30. RESVERLOGIX CORP CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 30.1 Resverlogix Corp Business Profile
- 30.2 Resverlogix Corp Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 30.2.1 Drug Snapshot
 - 30.2.1.1 Originator
 - 30.2.1.2 Collaborator/Co-Developer
 - 30.2.1.3 Route of Administration
 - 30.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 30.2.1.5 Area
 - 30.2.1.6 Type of Molecular Entity
- 30.3 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31. REVEN PHARMACEUTICALS INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 31.1 Reven Pharmaceuticals Inc Business Profile
- 31.2 Reven Pharmaceuticals Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 31.2.1 Drug Snapshot
 - 31.2.1.1 Originator
 - 31.2.1.2 Collaborator/Co-Developer
 - 31.2.1.3 Route of Administration

- 31.2.1.4 Orphan Drug/Fast Track/Special Designation
- 31.2.1.5 Area
- 31.2.1.6 Type of Molecular Entity
- 31.3 Current Status
- 31.4 Drug Overview
- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

32. SERVIER LABORATORIES LIMITED CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 32.1 Servier Laboratories Limited Business Profile
- 32.2 Servier Laboratories Limited Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 32.2.1 Drug Snapshot
 - 32.2.1.1 Originator
 - 32.2.1.2 Collaborator/Co-Developer
 - 32.2.1.3 Route of Administration
 - 32.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 32.2.1.5 Area
 - 32.2.1.6 Type of Molecular Entity
- 32.3 Current Status
- 32.4 Drug Overview
- 32.5 Drug Mechanism of Action
- 32.6 Clinical/Pre-clinical Trial Details
- 32.7 Latest Drug Developments

33. THE MEDICINES COMPANY CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 33.1 The Medicines Company Business Profile
- 33.2 The Medicines Company Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 33.2.1 Drug Snapshot
 - 33.2.1.1 Originator
 - 33.2.1.2 Collaborator/Co-Developer
 - 33.2.1.3 Route of Administration
 - 33.2.1.4 Orphan Drug/Fast Track/Special Designation

- 33.2.1.5 Area
- 33.2.1.6 Type of Molecular Entity
- 33.3 Current Status
- 33.4 Drug Overview
- 33.5 Drug Mechanism of Action
- 33.6 Clinical/Pre-clinical Trial Details
- 33.7 Latest Drug Developments

34. VASADE BIOSCIENCES CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 34.1 Vasade Biosciences Business Profile
- 34.2 Vasade Biosciences Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 34.2.1 Drug Snapshot
 - 34.2.1.1 Originator
 - 34.2.1.2 Collaborator/Co-Developer
 - 34.2.1.3 Route of Administration
 - 34.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 34.2.1.5 Area
 - 34.2.1.6 Type of Molecular Entity
- 34.3 Current Status
- 34.4 Drug Overview
- 34.5 Drug Mechanism of Action
- 34.6 Clinical/Pre-clinical Trial Details
- 34.7 Latest Drug Developments

35. VERSEON CORP CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 35.1 Verseon Corp Business Profile
- 35.2 Verseon Corp Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 35.2.1 Drug Snapshot
 - 35.2.1.1 Originator
 - 35.2.1.2 Collaborator/Co-Developer
 - 35.2.1.3 Route of Administration
 - 35.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 35.2.1.5 Area

- 35.2.1.6 Type of Molecular Entity
- 35.3 Current Status
- 35.4 Drug Overview
- 35.5 Drug Mechanism of Action
- 35.6 Clinical/Pre-clinical Trial Details
- 35.7 Latest Drug Developments

36. VESSL THERAPEUTICS LTD CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 36.1 VESSL Therapeutics Ltd Business Profile
- 36.2 VESSL Therapeutics Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 36.2.1 Drug Snapshot
 - 36.2.1.1 Originator
 - 36.2.1.2 Collaborator/Co-Developer
 - 36.2.1.3 Route of Administration
 - 36.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 36.2.1.5 Area
 - 36.2.1.6 Type of Molecular Entity
- 36.3 Current Status
- 36.4 Drug Overview
- 36.5 Drug Mechanism of Action
- 36.6 Clinical/Pre-clinical Trial Details
- 36.7 Latest Drug Developments

37. VIROMED CO LTD CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 37.1 ViroMed Co Ltd Business Profile
- 37.2 ViroMed Co Ltd Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 37.2.1 Drug Snapshot
 - 37.2.1.1 Originator
 - 37.2.1.2 Collaborator/Co-Developer
 - 37.2.1.3 Route of Administration
 - 37.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 37.2.1.5 Area
 - 37.2.1.6 Type of Molecular Entity

- 37.3 Current Status
- 37.4 Drug Overview
- 37.5 Drug Mechanism of Action
- 37.6 Clinical/Pre-clinical Trial Details
- 37.7 Latest Drug Developments

38. XYLOCOR THERAPEUTICS INC CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) PIPELINE DETAILS

- 38.1 XyloCor Therapeutics Inc Business Profile
- 38.2 XyloCor Therapeutics Inc Coronary Artery Disease (CAD) (Ischemic Heart Disease) Drug Details
 - 38.2.1 Drug Snapshot
 - 38.2.1.1 Originator
 - 38.2.1.2 Collaborator/Co-Developer
 - 38.2.1.3 Route of Administration
 - 38.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 38.2.1.5 Area
 - 38.2.1.6 Type of Molecular Entity
- 38.3 Current Status
- 38.4 Drug Overview
- 38.5 Drug Mechanism of Action
- 38.6 Clinical/Pre-clinical Trial Details
- 38.7 Latest Drug Developments

20. LATEST CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) DRUG PIPELINE DEVELOPMENTS, 2019

21. APPENDIX

- 21.1 About Us
- 21.2 Sources and Methodology
- 21.3 Contact Information

I would like to order

Product name: 2019 Future of Coronary Artery Disease (CAD)/Ischemic Heart Disease R&D Pipeline Drugs and Companies- Analysis of Global Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/289188BC885EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/289188BC885EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970